Compare · ABT vs SYRE
ABT vs SYRE
Side-by-side comparison of Abbott Laboratories (ABT) and Spyre Therapeutics Inc. (SYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and SYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $179.51B, about 20.0x SYRE ($8.98B).
- Over the past year, ABT is down 18.4% and SYRE is up 499.5% - SYRE leads by 517.8 points.
- ABT has hit the wire 2 times in the past 4 weeks while SYRE has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 10 for SYRE).
- Company
- Abbott Laboratories
- Spyre Therapeutics Inc.
- Price
- $103.11+2.27%
- $102.18+2.16%
- Market cap
- $179.51B
- $8.98B
- 1M return
- +13.92%
- +18.47%
- 1Y return
- -18.37%
- +499.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 2
- 0
- Recent ratings
- 25
- 10
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest SYRE
- Chief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $658,040 worth of shares (7,500 units at $87.74) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Sloan Sheldon exercised 8,334 shares at a strike of $27.46 and sold $730,896 worth of shares (8,334 units at $87.70) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Turtle Cameron sold $1,315,346 worth of shares (15,000 units at $87.69) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 582,540 units (SEC Form 4)
- Spyre Therapeutics Announces Grants of Inducement Awards
- Chief Financial Officer Burrows Scott L exercised 15,000 shares at a strike of $14.50 and sold $1,307,000 worth of shares (15,000 units at $87.13) (SEC Form 4)
- SEC Form S-3ASR filed by Spyre Therapeutics Inc.
- Director Fairmount Funds Management Llc converted options into 666,680 shares and sold $399,658,667 worth of shares (4,684,781 units at $85.31) (SEC Form 4)
- Director Henderson Michael Thomas sold $2,000,000 worth of shares (20,000 units at $100.00) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 68,606 units (SEC Form 4)
- Spyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients